AGC to Increase Biopharmaceutical CDMO Capability in Japan

Global corporation AGC  announced it will expand its biopharmaceutical CDMO capability in Yokohama, Japan. The decision is in line with the company&rsquo;s medium-term plan for positioning its biopharmaceutical CDMO arm as one of its strategic businesses. ACG is a manufacturer of electronics, glass, chemicals and biologics.
The total investment for the CDMO expansion is expected to be approximately 50 billion Japanese yen. Development services for gene and cell therapies is planned to begin first in 2025, followed by development and manufacturing services for mRNA pharmaceuticals, biopharmaceuticals made using mammalian cell cultures and gene and cell therapies in 2026.